CXCL5 and neoplasm: Fifteen days later, intraperitoneal injection of anti-CXCL5 neutralizing antibody or CXCR2 antagonist decreased the recruitment of subcutaneously injected RFP-LLC cells into the circulation and significantly prolonged the survival of tumour-bearing mice (Fig. 4f, g and Supplementary Fig. 3A).Treatment with anti-CXCL5 neutrlizing antibody and CXCR2 blockage also reduced the growth of primary tumours, indicating that CXCL5/CXCR2 could have effect on tumour growth other than chemotactic effects (Supplementary Fig. 3B, C, D).